
Overview
Diabetes management firm's preliminary Q4 net sales rose, beating analyst expectations
DME channel net sales expected to rise 23% yr/yr in the quarter
PBP channel net sales expected to rise yr/yr
Outlook
Company did not provide specific guidance for future quarters or full year 2026
Result Drivers
PBP CHANNEL GROWTH - PBP channel net sales expected to rise yr/yr, driven by increased reimbursement through this channel
INSTALLED BASE EXPANSION - Installed customer base expected to grow yr/yr, reflecting strong adoption of iLet Bionic Pancreas
NEW PATIENT STARTS - New patient starts expected to increase 36% yr/yr, with 69% coming from multiple daily injections
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net sales | Beat | $32 mln | $28.90 mln (10 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Beta Bionics Inc is $32.50, about 3.2% above its January 7 closing price of $31.49
Press Release: ID:nGNX9Dyf1M
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.